Cancer’s Vulnerability is Our Strength
Cyteir is developing the next generation of synthetic lethal therapies to treat cancer
Tumor mutations lead to DNA breaks that require repair for cancer cells to survive. This makes cancer cells vulnerable to targeted treatments that disrupt DNA damage response and repair. Cyteir treatments exploit this vulnerability by inducing synthetic lethality in tumor cells while sparing normal cells.
“The development and approval of PARP inhibitors have paved the way for additional, novel DNA repair and synthetic lethality-based therapies to address unmet needs in cancer treatment.”
Markus Renschler, MD
President and Chief Executive Office